Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2002 2
2003 4
2005 10
2006 16
2007 16
2008 24
2009 17
2010 23
2011 21
2012 7
2013 19
2014 17
2015 24
2016 28
2017 21
2018 19
2019 18
2020 18
2021 16
2022 10
2023 6
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

282 results

Results by year

Filters applied: . Clear all
Page 1
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
Judson I, Verweij J, Gelderblom H, Hartmann JT, Schöffski P, Blay JY, Kerst JM, Sufliarsky J, Whelan J, Hohenberger P, Krarup-Hansen A, Alcindor T, Marreaud S, Litière S, Hermans C, Fisher C, Hogendoorn PC, dei Tos AP, van der Graaf WT; European Organisation and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Judson I, et al. Lancet Oncol. 2014 Apr;15(4):415-23. doi: 10.1016/S1470-2045(14)70063-4. Epub 2014 Mar 5. Lancet Oncol. 2014. PMID: 24618336 Clinical Trial.
They were randomly assigned (1:1) by the minimisation method to either doxorubicin (75 mg/m(2) by intravenous bolus on day 1 or 72 h continuous intravenous infusion) or intensified doxorubicin (75 mg/m(2); 25 mg/m(2) per day, days 1-3) plus ifosfamide (10 g/m(2) over 4 days with …
They were randomly assigned (1:1) by the minimisation method to either doxorubicin (75 mg/m(2) by intravenous bolus on day 1 or 72 h continu …
Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia.
Jaramillo S, Benner A, Krauter J, Martin H, Kindler T, Bentz M, Salih HR, Held G, Köhne CH, Götze K, Lübbert M, Kündgen A, Brossart P, Wattad M, Salwender H, Hertenstein B, Nachbaur D, Wulf G, Horst HA, Kirchen H, Fiedler W, Raghavachar A, Russ G, Kremers S, Koller E, Runde V, Heil G, Weber D, Göhring G, Döhner K, Ganser A, Döhner H, Schlenk RF. Jaramillo S, et al. Blood Cancer J. 2017 May 26;7(5):e564. doi: 10.1038/bcj.2017.45. Blood Cancer J. 2017. PMID: 28548643 Free PMC article. Clinical Trial.
One hundred and seventy-six patients were treated with HDAC-135 and 392 patients with HDAC-123 with prophylactic pegfilgrastim at days 10 and 8, respectively, in the AMLSG 07-04 and the German AML Intergroup protocol. Time from start to chemotherapy until hematologic recov …
One hundred and seventy-six patients were treated with HDAC-135 and 392 patients with HDAC-123 with prophylactic pegfilgrastim at day …
A phase II study of modified FOLFIRINOX for chemotherapy-naïve patients with metastatic pancreatic cancer.
Ozaka M, Ishii H, Sato T, Ueno M, Ikeda M, Uesugi K, Sata N, Miyashita K, Mizuno N, Tsuji K, Okusaka T, Furuse J. Ozaka M, et al. Cancer Chemother Pharmacol. 2018 Jun;81(6):1017-1023. doi: 10.1007/s00280-018-3577-9. Epub 2018 Apr 9. Cancer Chemother Pharmacol. 2018. PMID: 29633005 Clinical Trial.
The primary endpoints were overall survival and the incidence of grade 3 or higher neutropenia. No patients received prophylactic pegfilgrastim. RESULTS: Sixty-nine pts. were enrolled from 39 institutions in Japan. The median overall survival was 11.2 months [95% confidenc …
The primary endpoints were overall survival and the incidence of grade 3 or higher neutropenia. No patients received prophylactic pegfilg …
Comparing the efficacy and side-effects of PDLASTA (Pegfilgrastim) with PDGRASTIM (Filgrastim) in breast cancer patients: a non-inferiority randomized clinical trial.
Najafi S, Ansari M, Kaveh V, Haghighat S. Najafi S, et al. BMC Cancer. 2021 Apr 23;21(1):454. doi: 10.1186/s12885-021-08197-6. BMC Cancer. 2021. PMID: 33892670 Free PMC article. Clinical Trial.
BACKGROUND: The objective of this study was to compare the efficacy and side effects of a single dose (Pegfilgrastim or PDL) or repeated six daily injections (Filgrastim or PDG) during chemotherapy courses in breast cancer patients in a non-inferiority clinical trial. ...
BACKGROUND: The objective of this study was to compare the efficacy and side effects of a single dose (Pegfilgrastim or PDL) or repea …
Pharmacokinetic and Pharmacodynamic Equivalence of Pegfilgrastim-cbqv and Pegfilgrastim in Healthy Subjects.
Finck B, Tang H, Civoli F, Hodge J, O'Kelly H, Vexler V. Finck B, et al. Adv Ther. 2020 Oct;37(10):4291-4307. doi: 10.1007/s12325-020-01459-y. Epub 2020 Aug 13. Adv Ther. 2020. PMID: 32789809 Clinical Trial.
This multicenter, randomized, single-blind, partial-reference-replicated, three-sequence crossover study assessed pharmacokinetic and pharmacodynamic bioequivalence of pegfilgrastim-cbqv and pegfilgrastim in healthy subjects. METHODS: One hundred twenty-two subjects …
This multicenter, randomized, single-blind, partial-reference-replicated, three-sequence crossover study assessed pharmacokinetic and pharma …
Biosimilar Pegfilgrastim-cbqv Demonstrated Similar Immunogenicity to Pegfilgrastim in Healthy Subjects Across Three Randomized Clinical Studies.
Civoli F, Finck B, Tang H, Hodge J, O'Kelly H, Vexler V. Civoli F, et al. Adv Ther. 2022 Mar;39(3):1230-1246. doi: 10.1007/s12325-021-02024-x. Epub 2022 Jan 16. Adv Ther. 2022. PMID: 35034311 Free PMC article. Clinical Trial.
As part of the totality of evidence that is required for regulatory approval of biosimilars, immunogenicity similarity must be assessed in the clinical programs. Pegfilgrastim-cbqv (UDENYCA()) is a pegfilgrastim biosimilar approved in the USA and European Union. ... …
As part of the totality of evidence that is required for regulatory approval of biosimilars, immunogenicity similarity must be assessed in t …
Plerixafor plus pegfilgrastim is a safe, effective mobilization regimen for poor or adequate mobilizers of hematopoietic stem and progenitor cells: a phase I clinical trial.
Herbert KE, Demosthenous L, Wiesner G, Link E, Westerman DA, Came N, Ritchie DS, Harrison S, Seymour JF, Prince HM. Herbert KE, et al. Bone Marrow Transplant. 2014 Aug;49(8):1056-62. doi: 10.1038/bmt.2014.112. Epub 2014 Jun 2. Bone Marrow Transplant. 2014. PMID: 24887382 Clinical Trial.
Comparison was with 22 historical controls (HC; lymphoma n=18, myeloma n=4; poor mobilizers n=4), mobilized with pegfilgrastim alone. Eight (67%) SP had PB CD34(+) count 5 10(6)/L D3 post pegfilgrastim; all SP surpassed this threshold the morning after plerixafor. . …
Comparison was with 22 historical controls (HC; lymphoma n=18, myeloma n=4; poor mobilizers n=4), mobilized with pegfilgrastim alone. …
A pharmacokinetics and pharmacodynamics equivalence trial of the proposed pegfilgrastim biosimilar, MYL-1401H, versus reference pegfilgrastim.
Waller CF, Tiessen RG, Lawrence TE, Shaw A, Liu MS, Sharma R, Baczkowski M, Kothekar MA, Micales CE, Barve A, Ranganna GM, Pennella EJ. Waller CF, et al. J Cancer Res Clin Oncol. 2018 Jun;144(6):1087-1095. doi: 10.1007/s00432-018-2643-3. Epub 2018 Apr 18. J Cancer Res Clin Oncol. 2018. PMID: 29671069 Clinical Trial.
METHODS: This phase 1, randomized, double-blind, three-way crossover trial in healthy volunteers evaluated the pharmacokinetics (PK), pharmacodynamics (PD), safety, and tolerability of the proposed biosimilar, comparing MYL-1401H, reference pegfilgrastim (Neulasta(), Amgen …
METHODS: This phase 1, randomized, double-blind, three-way crossover trial in healthy volunteers evaluated the pharmacokinetics (PK), pharma …
Efficacy and safety of pegfilgrastim biosimilar MD-110 in patients with breast cancer receiving chemotherapy: Single-arm phase III.
Takano T, Ito M, Kadoya T, Osako T, Aruga T, Masuda N, Miyaki T, Niikura N, Shimizu D, Yokoyama Y, Watanabe M, Tomomitsu M, Aogi K. Takano T, et al. Cancer Med. 2023 Oct;12(20):20242-20250. doi: 10.1002/cam4.6519. Epub 2023 Oct 12. Cancer Med. 2023. PMID: 37824431 Free PMC article. Clinical Trial.
INTRODUCTION: Pegfilgrastim is indicated to decrease the incidence of chemotherapy-induced febrile neutropenia. It is the first granulocyte-colony stimulating factor approved for prophylactic use regardless of carcinoma type and is marketed in Japan as G-LASTA (Kyowa Kirin …
INTRODUCTION: Pegfilgrastim is indicated to decrease the incidence of chemotherapy-induced febrile neutropenia. It is the first granu …
Efficacy of Plinabulin vs Pegfilgrastim for Prevention of Docetaxel-Induced Neutropenia in Patients With Solid Tumors: A Randomized Clinical Trial.
Blayney DW, Mohanlal R, Adamchuk H, Kirtbaya DV, Chen M, Du L, Ogenstad S, Ginn G, Huang L, Zhang Q. Blayney DW, et al. JAMA Netw Open. 2022 Jan 4;5(1):e2145446. doi: 10.1001/jamanetworkopen.2021.45446. JAMA Netw Open. 2022. PMID: 35084480 Free PMC article. Clinical Trial.
Plinabulin was well tolerated, with comparable safety to pegfilgrastim. CONCLUSIONS AND RELEVANCE: Plinabulin has comparable efficacy to pegfilgrastim for the prevention of CIN, with better safety and a better immunosuppressive profile. Plinabulin's same-day dosing …
Plinabulin was well tolerated, with comparable safety to pegfilgrastim. CONCLUSIONS AND RELEVANCE: Plinabulin has comparable efficacy …
282 results